Copyright © 2026 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{200012,
        author = {Dr. Rajkumar V. Shete and Dr. Mahesh M. Ghaisas and Prof. Shrikant R. Borate and Mr. Abhishek P. Bhor},
        title = {Neuroprotective Potential of Cardamonin in Experimental Models of Parkinson’s Disease: A Comprehensive Review},
        journal = {International Journal of Innovative Research in Technology},
        year = {2026},
        volume = {12},
        number = {12},
        pages = {73-82},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=200012},
        abstract = {Parkinson’s disease (PD) is a chronic and progressive neurodegenerative disorder characterized by the selective degeneration of dopaminergic neurons in the substantia nigra, leading to motor impairments such as tremors, rigidity, and bradykinesia, along with non-motor complications. The present review explores the neuroprotective potential of cardamonin, a naturally occurring chalcone, in experimental models of Parkinson’s disease induced by reserpine and haloperidol in mice. These pharmacological models are widely utilized to mimic Parkinsonian pathology by depleting monoamine neurotransmitters and antagonizing dopamine receptors, thereby replicating key features of dopaminergic dysfunction and oxidative stress observed in PD.  
Cardamonin has gained significant attention due to its diverse pharmacological properties, including antioxidant, anti-inflammatory, and anti-apoptotic activities. This review comprehensively discusses the molecular mechanisms underlying its neuroprotective effects, such as attenuation of oxidative stress through the enhancement of endogenous antioxidant defenses, suppression of pro-inflammatory mediators, and inhibition of neuronal apoptosis. Additionally, cardamonin’s ability to restore dopamine levels and improve motor coordination and behavioral deficits in experimental animals is critically evaluated. Overall, the available evidence suggests that cardamonin holds considerable promise as a potential therapeutic agent for the prevention and management of Parkinson’s disease. However, further in-depth preclinical studies and well-designed clinical trials are essential to establish its safety profile, efficacy, and translational potential in human subjects.},
        keywords = {Cardamonin, Parkinson’s disease, Neuroprotection, Reserpine, Haloperidol, Oxidative stress, Dopaminergic neurons.},
        month = {May},
        }